• Founded: 2016
  • Location: Boston, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin2
  • Therapy area: Parkinson's
  • Drug types: NEU, PSY
  • Lead product: CVN424
  • Product link: https://www.cerevance.com/pipeline
  • Funding: $51M B Feb 2023; $20M B Jul 2020; $45M B Apr 2020; $36M A Dec 2016
  • Investors: Gates Frontier, Dementia Discovery Fund, Foresite Capital, GV, Lightstone Ventures, Takeda Ventures, UPMC Enterprises, Dolby Family Ventures



job board

Short description:

CNS small molecules

Drug notes:

CVN766 Clin1 schizophrenia; CVN-293 Clin0 ALS, Alzheimer's; CVN398 RD/Clin0 Parkinson's; 3+ undisclosed programs RD Parkinson's, Alzheimer's, undisclosed

Long description:

Cerevance uses their Nuclear Enriched Transcript Sort sequencing (NETSseq) platform and machine learning to discover the next generation of central nervous system disease treatments. They advertise to have one of the world’s largest proprietary databases of brain tissue with about sixty brain cell types and 14,000 tissue samples. Cerevance is a Boston-based biotech founded in 2016.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com